Revenio Group Corporation, Managers' transactions, August 22, 2017 at 08:00 am EET
Revenio Group Oyj - Managers' Transactions
____________________________________________
Person subject to the notification requirement
Name: Joensuun Kauppa ja Kone Oy
Position: Closely associated person
(X) Legal person
(1):Closely associated person
Name: Kakkonen, Kyösti
Position: Member of the Board
Issuer: Revenio Group Oyj
LEI: 743700I27E0FWSXLKK04
Notification type: INITIAL NOTIFICATION
Reference number: 743700I27E0FWSXLKK04_20170821132658_4
____________________________________________
Transaction date: 2017-08-18
Venue: NASDAQ HELSINKI LTD (XHEL)
Instrument type: SHARE
ISIN: FI0009010912
Nature of the transaction: ACQUISITION
Transaction Details
(1): Volume: 1000 Unit price: 36,67230 EUR
Aggregated transactions
(1): Volume: 1000 Volume weighted average price: 36.67230 EUR
____________________________________________
Person subject to the notification requirement
Name: Joensuun Kauppa ja Kone Oy
Position: Closely associated person
(X) Legal person
(1):Closely associated person
Name: Kakkonen, Kyösti
Position: Member of the Board
Issuer: Revenio Group Oyj
LEI: 743700I27E0FWSXLKK04
Notification type: INITIAL NOTIFICATION
Reference number: 743700I27E0FWSXLKK04_20170821132658_4
____________________________________________
Transaction date: 2017-08-18
Venue: NASDAQ HELSINKI LTD (XHEL)
Instrument type: SHARE
ISIN: FI0009010912
Nature of the transaction: ACQUISITION
Transaction Details
(1): Volume: 1000 Unit price: 36,67230 EUR
Aggregated transactions
(1): Volume: 1000 Volume weighted average price: 36.67230 EUR
For further information, please contact: Robin Pulkkinen, CFO, +358 50 5059932
Distribution:
Nasdaq Helsinki
The Revenio Group in brief
Revenio is a Finnish, globally operating health technology corporation whose worldwide success is based on a strongly patented intraocular pressure measurement technology. The Revenio Group consists of Icare Finland Oy, Revenio Research Oy and Oscare Medical Oy, in which Revenio holds a 53.5% interest. The common denominators of Revenio's business operations include screening, follow-up and the global need to make cost savings through preventive health care. Revenio seeks vigorous growth in health technology. Revenio aims to develop even more efficient and easily adopted methods for the early-stage detection of diseases with significance for public health. The focus of Revenio's screening technology is on the early detection of glaucoma, osteoporosis, skin cancer and asthma, and the monitoring of these during the treatment process.
In 2016, Revenio Group's net sales totaled MEUR 23.4, with its operating profit for continuing operations standing at 30.1%. Revenio Group Corporation is listed on Nasdaq Helsinki.